AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc., a leading, privately held clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced today the publication of new preclinical data suggesting that microRNA-34 (miR-34) and erlotinib, an EFGR inhibitor approved to treat non-small cell lung cancer (NSCLC), cooperate synergistically to inhibit proliferation of certain erlotinib-resistant NSCLC cells and hepatocellular carcinoma (HCC) cells in vitro. The data, published in the online journal PLOS ONE, demonstrate how a therapeutic microRNA may help address drug resistance and increase the efficacy of single-gene targeted cancer therapy.
Help employers find you! Check out all the jobs and post your resume.
